$AEMD News

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript

Aethlon Medical Q1 EPS $(4.02) Misses $(0.79) Estimate; Cash & Equivalents $4.9M

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Patients In Aethlon Medical's Second Cohort Of Its Australian Oncology Feasibility Study Demonstrated Biological Changes

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical Prices $4M Follow-On Offering Of 5,633,009 Shares And Warrants At $0.7101 Per Unit

Aethlon Medical Files Prospectus For Offering Mixed Shelf

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Aethlon Medical Publishes Peer-Reviewed Research Demonstrating Novel Long COVID Biomarker And Potential Therapeutic Target For Hemopurifier In International Journal of Molecular Sciences

Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...

AEMD: Clinical Study Advances to Final Cohort; Preclinical Activities Expand

Aethlon Medical, Inc. Q4 2026 Earnings Call Summary

Aethlon (AEMD) Q4 2026 Earnings Transcript

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript

Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026